Skip to main content
. 2024 Mar 28;16(7):1329. doi: 10.3390/cancers16071329

Table 3.

Pathological characteristics and follow-up of 212 patients with pT4a bladder cancer treated with open (102 patients) vs. robot-assisted (110 patients) radical cystectomy.

Variables Group A
ORC
(n = 102)		 Group B
RARC
(n = 110)		 p
Histotype

  • Urothelial cancer

  • Adenocarcinoma

  • Squamous cell

  • Sarcomatoid

 n (%)
63 (61.8)
2 (1.9)
28 (27.5)
9 (8.8)
70 (63.6)
3 (2.7)
27 (24.6)
10 (9.1)
0.13
0.20
0.21
0.19
Lymph node invasion n (%) 55 (53.9) 57 (51.8) 0.18
pN

  • pN1

  • pN2

 n (%)
40 (39.2)
15 (14.7)
45 (40.9)
12 (10.9)
0.16
0.14
Positive margins

  • Prostate base

  • Mid-prostate

 n (%) 22 (21.6)
17 (16.7)
5 (4.9)		 12 (10.9)
9 (8.2)
3 (2.7)		 0.05
0.04
0.10
Neoadjuvant CT n (%) 8 (7.8) 12 (10.9) 0.07
Adjuvant CT

  • Gemcitabine + Cisplatin

  • Gemcitabine + Carboplatin

 n (%) 24 (23.5)
9 (8.8)
15 (14.7)		 24 (21.8)
11 (10.0)
13 (11.8)		 0.09
Adjuvant RT n (%) 5 (4.9) 6 (5.5) 0.14
Follow-up, months Mean (SD) 72.3 (23.9) 65.9 (17.4) 0.06
90-day mortality n (%) 11 (10.8) 9 (8.2) 0.12
Status at last follow-up

  • Alive without disease

  • Alive with disease

  • Death for cancer

  • Death for other cause

 n (%)
26 (25.5)
14 (13.7)
52 (51.0)
10 (9.8)
30 (27.3)
19 (17.3)
49 (44.5)
12 (10.9)
0.19
0.10
0.21
0.24

ORC = open radical cystectomy, RARC = robot-assisted radical cystectomy, CT = chemotherapy, RT = radiotherapy, SD = standard deviation.